Pharmaceutical Research Associates Magyarorszag
- Address
- lock Available on a paid plan
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
The site is advancing treatments for rare inherited conditions, notably hereditary angioedema, by testing innovative biologic agents that aim to reduce attack frequency and improve patient quality of life.
- Evaluation of a novel kallikrein inhibitor for hereditary angioedema
- Safety and tolerability assessment in healthy volunteers
- Comparative pharmacokinetic study of biosimilar products
Pharmaceutical Research Associates Magyarorszag leverages its expertise in rare disease research to support patients and clinicians seeking better therapeutic options.
Immune System Diseases
Research at this Budapest facility explores immune modulation, including combination strategies with pembrolizumab and novel antibodies targeting TNF receptor 2, to enhance anti‑tumor immunity.
- Monoclonal antibody development for immune checkpoint enhancement
- Combination therapy safety profiling
- Biomarker-driven patient selection studies
The program aims to broaden therapeutic options for patients with immune‑mediated cancers and disorders.
Musculoskeletal Diseases
Clinical investigations focus on novel anti‑inflammatory compounds intended to alleviate pain and improve joint function in musculoskeletal conditions.
- First‑in‑human safety trials of small‑molecule inhibitors
- Pharmacodynamic evaluation of targeted therapies
- Exploratory studies on biomarkers of cartilage degradation
By integrating patient‑reported outcomes, the research supports more effective management of arthritis and related disorders.
Neoplasms
A major research focus is on advanced solid tumors, with studies assessing new monoclonal antibodies, mass‑balance profiling, and the impact of genetic alterations on drug behavior.
- Mass balance and bioavailability studies in solid tumor patients
- Evaluation of a TNFR2‑targeted antibody as monotherapy and with checkpoint inhibitors
- Pharmacogenomic investigations of MTAP‑deleted tumors
These efforts aim to identify effective treatment regimens and optimize dosing strategies for difficult‑to‑treat cancers.
Skin and Connective Tissue Diseases
The center conducts trials on innovative peptide and biologic formulations designed to treat skin disorders and connective tissue abnormalities, emphasizing safety and patient convenience.
- Oral extended‑release peptide bioavailability assessments
- Food‑effect studies on dermatologic drug delivery
- Comparative analysis of biosimilar versus reference products
Findings from these studies contribute to improved therapeutic options for conditions such as psoriasis and systemic sclerosis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1BioInvent International AB1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pharvaris Netherlands B.V.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Pharmaceutical Research Associates Magyarorszag
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Bioavailability Assessment of Deucrictibant Formulations in Hereditary Angioedema: A Phase I, Open-Label, Randomized, Cross-Over Study in Healthy Subjects | Pharvaris Netherlands B.V. | Phase I | Not Recruiting | Jun 2024 | Jul 2024 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bi-1808 | 1 | Unknown | 2020-04-09 | 2020-04-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.